Article
Biophysics
Sarah Farag, Ulrike Bacher, Barbara Jeker, Myriam Legros, Gaelle Rhyner, Jean-Marc Luthi, Julian Schardt, Thilo Zander, Michael Daskalakis, Behrouz Mansouri, Chantal Manz, Thomas Pabst
Summary: This study compared the efficacy of combining bendamustine with melphalan to melphalan alone in the treatment of multiple myeloma. The results showed that the combination therapy significantly improved the complete remission rate and stringent complete remission rate/response rate in patients.
BONE MARROW TRANSPLANTATION
(2022)
Article
Biophysics
Charalampos Charalampous, Utkarsh Goel, Morie Gertz, Martha Lacy, Angela Dispenzieri, Suzanne Hayman, David Dingli, Francis Buadi, Prashant Kapoor, Taxiarchis Kourelis, Rahma Warsame, William J. Hogan, Shaji Kumar
Summary: This study examined the impact of the time interval between the end of induction therapy and autologous hematopoietic transplantation on the survival of multiple myeloma patients. The results showed that a shorter interval was associated with a longer progression-free survival, particularly for patients with a partial response during induction.
BONE MARROW TRANSPLANTATION
(2023)
Article
Biophysics
Nico Gagelmann, Diderik-Jan Eikema, Liesbeth C. de Wreede, Alessandro Rambaldi, Simona Iacobelli, Linda Koster, Denis Caillot, Didier Blaise, Peter Rememyi, Claude-Eric Bulabois, Jakob Passweg, Xavier Leleu, Samo Zver, Guido Kobbe, Per Ljungman, Patrice Chevallier, Mark Ringhoffer, Murray Martin, Urpu Salmenniemi, Xavier Poire, Stig Lenhoff, Pietro Pioltelli, Nicola Mordini, Michel Delforge, Laurent Garderet, Stefan Schoenland, Ibrahim Yakoub-Agha, Nicolaus Kroeger
Summary: The study found that for patients with t(4;14), tandem autologous and tandem autologous/reduced-intensity allogeneic transplantation were associated with better progression-free survival (PFS), while for patients with del(17p), there was no significant difference in outcome.
BONE MARROW TRANSPLANTATION
(2021)
Article
Hematology
Joselle Cook, Isla Johnson, Alexandra Higgins, Surbhi Sidana, Rahma Warsame, Wilson Gonsalves, Morie A. Gertz, Francis Buadi, Martha Lacy, Prashant Kapoor, Angela Dispenzieri, Taxiarchis Kourelis, David Dingli, Amie Fonder, Suzanne Hayman, Miriam Hobbs, Yi Lisa Hwa, Robert Kyle, Nelson Leung, Ronald Go, Vincent S. Rajkumar, Shaji Kumar
Summary: This study retrospectively analyzed 555 newly diagnosed multiple myeloma patients treated with VRd, comparing different schedules of bortezomib administration. While once weekly bortezomib showed better response rates, there was no significant impact on PFS or OS with varying administration schedules.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Immunology
Rui Zhao, Jing Zhao, Yichuan Song, Wenxuan Fu, Qingtao Wang, Rui Zhang
Summary: This study aimed to find laboratory indicators that could predict disease progression in newly diagnosed multiple myeloma patients who underwent autologous stem cell transplantation (ASCT). The results showed that certain inflammation-related indicators, such as ANC, NLR, SIRI, and LMR, can serve as potential biomarkers for predicting the progression-free survival (PFS) of these patients.
JOURNAL OF INFLAMMATION RESEARCH
(2023)
Article
Biophysics
Annamaria Brioli, Felix vom Hofe, Paola Rucci, Thomas Ernst, Olaposi Yomade, Inken Hilgendorf, Sebastian Scholl, Herbert Sayer, Lars-Olof Muegge, Andreas Hochhaus, Marie von Lilienfeld-Toal
Summary: The study confirmed that autologous stem cell transplantation conditioned with melphalan 200 mg/m(2) (Mel200) remains the standard treatment for eligible myeloma patients, showing better treatment response and longer survival compared to lower doses of melphalan (MelRed).
BONE MARROW TRANSPLANTATION
(2021)
Article
Oncology
Song-Yau Wang, Tanja Holzhey, Simone Heyn, Thomas Zehrfeld, Susann Fricke, Franz Albert Hoffmann, Cornelia Becker, Leanthe Braunert, Thomas Edelmann, Inessa Paulenz, Marcus Hitzschke, Franziska Flade, Andreas Schwarzer, Klaus Fenchel, Georg-Nikolaus Franke, Vladan Vucinic, Madlen Jentzsch, Sebastian Schwind, Saskia Hell, Donata Backhaus, Thoralf Lange, Dietger Niederwieser, Markus Scholz, Uwe Platzbecker, Wolfram Poenisch
Summary: Autologous stem cell transplantation (ASCT) is the standard treatment for younger patients with newly diagnosed multiple myeloma (MM). However, many eligible patients are excluded from transplant studies due to restrictive exclusion criteria. This retrospective analysis included 540 MM patients who received ASCT between 1996 and 2019.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Oncology
Abdul Hamid Bazarbachi, Rama Al Hamed, Florent Malard, Ali Bazarbachi, Jean-Luc Harousseau, Mohamad Mohty
Summary: The current standard of care for newly diagnosed fit multiple myeloma patients involves induction, high dose melphalan, autologous stem cell transplantation, and maintenance. Triplet or quadruplet regimens featuring proteasome inhibitor bortezomib and dexamethasone are favored. Quadruplet regimens with anti-CD38 monoclonal antibodies show promise.
BLOOD CANCER JOURNAL
(2022)
Article
Biophysics
Vanille Laurent, Clementine Fronteau, Chloe Antier, Pascale Dupuis, Benoit Tessoulin, Thomas Gastinne, Beatrice Mahe, Nicolas Blin, Viviane Dubruille, Anne Lok, Patrice Chevallier, Thierry Guillaume, Alice Garnier, Pierre Peterlin, Amandine Le Bourgeois, Sophie Vantyghem, Mourad Tiab, Pascal Godmer, Sophie Sadot, Marion Loirat, Adrien Trebouet, Nicolas Cormier, Steven Le Gouill, Philippe Moreau, Cyrille Touzeau
Summary: The triplet-drug regimens VTD and VRD are standard of care induction prior to ASCT in myeloma. VRD induction was associated with more frequent use of plerixafor, increased number of apheresis, and higher collection failure rate compared to VTD. The median number of CD34-positive cells was lower in the VRD group, although the majority of patients in both groups underwent ASCT. Optimizing stem-cell collection strategy is crucial, especially in the context of tandem transplantation and incorporating anti-CD38 monoclonal antibody into induction.
BONE MARROW TRANSPLANTATION
(2021)
Article
Immunology
Simone A. Minnie, Geoffrey R. Hill
Summary: The incidence of multiple myeloma is increasing globally, with substantial morbidity and mortality and remains largely incurable. Autologous stem cell transplantation (ASCT) has been shown to provide a progression free survival benefit in eligible patients beyond novel therapies. ASCT results in immune effects beyond cytoreduction, highlighting the potential for new immunotherapy maintenance strategies to prevent myeloma progression.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Xianghua Huang, Guisheng Ren, Wencui Chen, Jinzhou Guo, Liang Zhao, Caihong Zeng, Yongchun Ge, Zhihong Liu
Summary: Induction therapy with bortezomib may benefit AL amyloidosis patients with low disease burden eligible for ASCT, showing significantly improved efficacy and survival rates compared to other induction therapies or no induction therapy.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
(2021)
Article
Oncology
Julie Cote, Richard LeBlanc, Hira Mian, Michael P. Chu, Arleigh McCurdy, Esther Masih-Khan, Jiandong Su, Victor H. Jimenez-Zepeda, Kevin Song, Martha Louzada, Darrell White, Michael Sebag, Anthony Reiman, Julie Stakiw, Rami Kotb, Debra Bergstrom, Muhammad Aslam, Rayan Kaedbey, Christopher P. Venner, Engin Gul, Donna Reece
Summary: This study analyzed the details and outcomes of autologous stem cell transplant (ASCT) as first-line therapy in multiple myeloma (MM) patients. The results showed that lenalidomide-based maintenance therapy can improve patients' survival, and undergoing multiple induction regimens after transplant does not improve outcomes.
BLOOD CANCER JOURNAL
(2023)
Article
Oncology
Marc-Andrea Baertsch, Elias K. Mai, Thomas Hielscher, Uta Bertsch, Hans J. Salwender, Markus Munder, Stephan Fuhrmann, Ulrich Duehrsen, Peter Brossart, Kai Neben, Jana Schlenzka, Christina Kunz, Marc S. Raab, Jens Hillengass, Anna Jauch, Anja Seckinger, Dirk Hose, Steffen Luntz, Pieter Sonneveld, Henk Lokhorst, Hans Martin, Martin Goerner, Martin Hoffmann, Hans-Walter Lindemann, Helga Bernhard, Igor W. Blau, Christof Scheid, Britta Besemer, Katja C. Weisel, Mathias Haenel, Jan Duerig, Hartmut Goldschmidt
Summary: In patients with multiple myeloma post autologous stem cell transplantation, maintenance treatment with bortezomib and lenalidomide showed no significant difference in progression-free survival and overall survival.
BLOOD CANCER JOURNAL
(2021)
Article
Nutrition & Dietetics
Gwendolyn N. Y. van Gorkom, Lara S. Boerenkamp, Birgit L. M. G. Gijsbers, Heidi H. van Ojik, Will K. W. H. Wodzig, Lotte Wieten, Catharina H. M. J. Van Elssen, Gerard M. J. Bos
Summary: Vitamin C supplementation did not show beneficial effects on immune recovery in autologous hematopoietic stem cell transplantation (HSCT) patients, but may reduce the incidence of bacteremia.
Article
Oncology
Lakshmi Yarlagadda, Sravani Gundarlapalli, Richa Parikh, Reid D. Landes, Mathew Kottarathara, Yetunde Ogunsesan, Shadiqul Hoque, Angel A. Mitma, Clyde Bailey, Kerri M. Hill, Sharmilan Thanendrarajan, Monica Graziutti, Meera Mohan, Maurizio Zangari, Frits van Rhee, Guido Tricot, Carolina Schinke
Summary: Multiple Myeloma (MM) is a common cancer of the bone marrow that remains incurable despite advancements in therapy. While Daratumumab has improved survival rates, heavily pretreated patients who progress on this treatment have poor clinical outcomes. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) may be a viable treatment option for selected patients who are refractory to Daratumumab.
Article
Oncology
Inge Oudaert, Hatice Satilmis, Philip Vlummens, Wouter De Brouwer, Anke Maes, Dirk Hose, Elke De Bruyne, Bart Ghesquiere, Karin Vanderkerken, Kim De Veirman, Eline Menu
Summary: This study identified a correlation between PYCR1/2 mRNA expression and overall survival in multiple myeloma (MM) patients. In vitro experiments showed that inhibition of PYCR1 reduced MM cell viability and proliferation, and increased apoptosis. Additionally, combination therapy of PYCR1 inhibitor with bortezomib showed promising results in reducing tumor burden.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Hematology
Jacob Stroh, Anja Seckinger, Michael Heider, Martina Rudelius, Ruth Eichner, Markus Schick, Jolanta Slawska, Martina Emde-Rajaratnam, Hans Salwender, Uta Bertsch, Hartmut Goldschmidt, Katja Weisel, Christof Scheid, Ulrich Keller, Dirk Hose, Florian Bassermann
Summary: In this study, researchers found that MCT1 expression levels were correlated with the survival of patients with multiple myeloma (MM) receiving lenalidomide maintenance therapy. High expression levels of MCT1 were associated with shorter progression-free survival (PFS) and overall survival (OS) in cases with lenalidomide maintenance. However, MCT1 expression did not significantly impact PFS or OS in cases with bortezomib maintenance. These findings suggest that MCT1 can serve as a predictive marker for response to lenalidomide-based maintenance therapy in MM patients.
Article
Biochemistry & Molecular Biology
Felix Jenne, Sergey Biniaminov, Nathalie Biniaminov, Philipp Marquardt, Clemens Von Bojnicic-Kninski, Roman Popov, Anja Seckinger, Dirk Hose, Alexander Nesterov-Mueller
Summary: A novel resemblance-ranking peptide library was designed to search for selective binders to antibodies. The library was synthesized with ultra-high-density peptide arrays, and screens for selective binders were performed for the therapeutic anti-CD20 antibody rituximab. The amino acid composition of antibody-binding peptides was analyzed, and the affinity of rituximab was found to increase with an increase in hydrophobic amino acids. Substitutional analysis revealed a specific hydrophobic epitope for rituximab. Conformational binders similar to the target of rituximab were also investigated. The library has the potential to screen for potential linear epitopes and provide information about antibody cross-reactivity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Economics
Mimi Choon-Quinones, Dirk Hose, Zoltan Kalo, Tamas Zelei, Jean-Luc Harousseau, Brian Durie, Paul Keown, Mike Barnett, Ivett Jakab
Summary: Decision-aids (DAs) can assist in shared decision-making by providing evidence-based information for healthcare professionals, patients, and caregivers. However, current DAs lack a comprehensive framework of decision factors.
Article
Oncology
Elias K. Mai, Stefanie Huhn, Kaya Miah, Alexandra M. Poos, Christof Scheid, Katja C. Weisel, Uta Bertsch, Markus Munder, Oscar Berlanga, Dirk Hose, Anja Seckinger, Anna Jauch, Igor W. Blau, Mathias Haenel, Hans J. Salwender, Axel Benner, Marc S. Raab, Hartmut Goldschmidt, Niels Weinhold
Summary: Mass spectrometry (MS) is a promising tool for monitoring monoclonal protein in plasma cell dyscrasias. Our study found that MS negativity was significantly associated with improved progression-free survival (PFS) in multiple myeloma patients, even in those patients with complete response (CR). Combining MS and baseline cytogenetics improved the prediction of outcome, and sequential MS combined with baseline disease features and minimal residual disease (MRD) can further improve its clinical value.
BLOOD CANCER JOURNAL
(2023)
Review
Economics
Mimi Choon-Quinones, Tamas Zelei, Bertalan Nemeth, Manna Toth, Xiao Yang Jia, Mike Barnett, Paul Keown, Brian Durie, Jean-Luc Harousseau, Dirk Hose, Zoltan Kalo
Summary: The aim of this study was to review economic evaluations of health technologies in multiple myeloma (MM) and provide recommendations for future analyses. A systemic literature review was conducted and it was found that most economic analyses were from high-income countries, while evaluations from middle-income countries were rare. Diagnostic technologies and integrated care were rarely modelled, and there was a lack of evaluations regarding minimal residual disease (MRD).
JOURNAL OF MEDICAL ECONOMICS
(2023)
Article
Oncology
Rong Fan, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Philip Vlummens, Anke Maes, Catharina Muylaert, Elke De Bruyne, Eline Menu, Holly Evans, Andrew Chantry, Nathan De Beule, Dirk Hose, Marie Toerngren, Helena Eriksson, Karin Vanderkerken, Ken Maes, Karine Breckpot, Kim De Veirman
Summary: This study reveals the dual therapeutic effects of the immunomodulator tasquinimod in multiple myeloma patients, including inhibition of tumor cell proliferation and promotion of immune activity. The results suggest that tasquinimod can inhibit immunosuppressive myeloid cells in the bone marrow by targeting S100A9, and enhance T cell activity and functionality.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Alejandra Mendez Romero, Bronno van der Holt, Francois E. J. A. Willemssen, Rob A. de Man, Ben J. M. Heijmen, Steven Habraken, Henrike Westerveld, Otto M. van Delden, Heinz-Josef Klumpen, Eric T. T. L. Tjwa, Petra M. Braam, Sjoerd F. M. Jenniskens, Thomas Vanwolleghem, Reinhilde Weytjens, Olivier d'Archambeau, Judith de Vos-Geelen, Jeroen Buijsen, Christiaan van der Leij, Wilhelm den Toom, Dave Sprengers, Jan N. M. Ijzermans, Adriaan Moelker
Summary: In this multicenter randomized trial, the efficacy of transarterial chemoembolization delivered with drug eluting beads (TACE-DEB) was compared with stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma (HCC). The study found that SBRT showed higher local antitumoral activity than TACE-DEB, without detrimental effects on overall survival (OS), toxicity, and quality of life (QoL).
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Oncology
J. L. van Dam, E. M. M. Verkolf, E. N. Dekker, B. A. Bonsing, S. O. Bratlie, L. A. A. Brosens, O. R. Busch, L. M. J. W. van Driel, C. H. J. van Eijck, S. Feshtali, P. Ghorbani, D. J. A. de Groot, J. W. B. de Groot, B. C. M. Haberkorn, I. H. de Hingh, B. van der Holt, T. M. Karsten, M. B. van der Kolk, K. J. Labori, M. S. L. Liem, O. J. L. Loosveld, I. Q. Molenaar, M. B. Polee, H. C. van Santvoort, J. de Vos Geelen, M. L. Wumkes, G. van Tienhoven, M. Y. V. Homs, M. G. Besselink, J. W. Wilmink, B. Groot Koerkamp, Dutch Pancreatic Cancer Grp
Summary: This study aims to compare the effectiveness of adjuvant chemotherapy after surgery and neoadjuvant chemotherapy followed by surgery. The objective is to find the optimal approach for the treatment of resectable pancreatic cancer.
Article
Oncology
Niels W. C. J. van de Donk, Monique C. Minnema, Bronno van der Holt, Fredrik Schjesvold, Ka Lung Wu, Annemiek Broijl, Wilfried W. H. Roeloffzen, Alain Gadisseur, Giuseppe Pietrantuono, Ludek Pour, Vincent H. J. van der Velden, Thomas Lund, Massimo Offidani, Mariella Grasso, Luisa Giaccone, Wida Razawy, Paola Tacchetti, Katia Mancuso, Trine Silkjaer, Jo Caers, Sonja Zweegman, Roman Hajek, Reuben Benjamin, Annette Juul Vangsted, Mario Boccadoro, Francesca Gay, Pieter Sonneveld, Pellegrino Musto
Summary: The EMN12/HOVON-129 study aimed to improve the prognosis of patients with primary plasma cell leukemia by incorporating carfilzomib and lenalidomide in their treatment. The results showed a significant improvement in progression-free survival compared to previously published data. However, the prognosis of primary plasma cell leukemia remains inferior to that of multiple myeloma.
Article
Immunology
Aniko Sijs-Szabo, Avinash G. Dinmohamed, Jurjen Versluis, Bronno van der Holt, Mar Bellido, Mette D. Hazenberg, Michel van Gelder, Nicolaas P. M. Schaap, Ellen Meijer, Lotte E. van der Wagen, Constantijn J. M. Halkes, Anita W. Rijneveld, Jan J. Cornelissen
Summary: In this retrospective study, RIC-alloHSCT was compared with MAC-alloHSCT in older adult patients with acute lymphoblastic leukemia. The results showed that RIC-alloHSCT had lower nonrelapse mortality but a significantly higher relapse rate compared to MAC-alloHSCT. These findings suggest that MAC-alloHSCT may be a more effective consolidation therapy for reducing relapse.
Article
Medicine, General & Internal
Pablo R. Kappen, M. Mos, Johannes Jeekel, Clemens M. F. Dirven, Steven A. Kushner, Robert-Jan Osse, Michiel Coesmans, Marten J. Poley, Mathijs S. van Schie, Bronno van der Holt, M. Klimek, Arnaud J. P. E. Vincent
Summary: A prospective randomized controlled trial found that playing preferred music before, during, and after neurosurgery can reduce the risk of delirium after craniotomy, but this effect was not significant when using the DSM-5 diagnostic criteria. Music also increased heart rate variability. The validation of delirium screening tools and evaluation of long-term implications after craniotomy are needed.
Letter
Hematology
Kazimierz Groen, Fredrik H. Schjesvold, Bronno Van der Holt, Mark-David Levin, Maarten R. Seefat, Markus Hansson, Maria B. L. Leys, Josien C. Regelink, Anders Waage, Damian Szatkowski, Per Axelsson, Trung Hieu Do, Asta Svirskaite, Ellen Van der Spek, Einar Haukas, Dorota Knut-Bojanowska, Paula F. Ypma, Cecilie H. Blimark, Ulf-Henrik Mellqvist, Niels W. C. J. Van de Donk, Pieter Sonneveld, Anja Klostergaard, Annette J. Vangsted, Niels Abildgaard, Sonja Zweegman
Letter
Hematology
Kazimierz Groen, Fredrik H. Schjesvold, Bronno van der Holt, Mark-David Levin, Maarten R. Seefat, Markus Hansson, Maria B. L. Leys, Josien C. Regelink, Anders Waage, Damian Szatkowski, Per Axelsson, Trung Hieu Do, Asta Svirskaite, Ellen van der Spek, Einar Haukas, Dorota Knut-Bojanowska, Paula F. Ypma, Cecilie H. Blimark, Ulf-Henrik Mellqvist, Niels W. C. J. van de Donk, Pieter Sonneveld, Anja Klostergaard, Annette J. Vangsted, Niels Abildgaard, Sonja Zweegman
Article
Oncology
Elias K. Mai, Thomas Hielscher, Uta Bertsch, Hans J. Salwender, Sonja Zweegman, Marc S. Raab, Markus Munder, Lucia Pantani, Katia Mancuso, Peter Brossart, Meral Beksac, Igor W. Blau, Jan Duerig, Britta Besemer, Roland Fenk, Peter Reimer, Bronno van der Holt, Mathias Haenel, Ivana von Metzler, Ullrich Graeven, Carsten Mueller-Tidow, Mario Boccadoro, Christof Scheid, Meletios A. Dimopoulos, Jens Hillengass, Katja C. Weisel, Michele Cavo, Pieter Sonneveld, Hartmut Goldschmidt
Summary: This study examines the incidence and causes of morbidity and mortality during induction therapy for newly diagnosed multiple myeloma (NDMM). It develops and validates a predictive risk score to identify NDMM patients at risk of severe infections or death. The study identifies four major risk factors and stratifies patients into low, intermediate, and high-risk groups. The risk score is validated in multiple trials incorporating quadruplet induction therapies.